Bunaharitake

Metadata

Regulatory Status

Japan

• Status: Recognized as an edible mushroom (Bunaharitake). Available in specialty markets during summer and autumn cultivation seasons.
• Cultivation: Successfully cultivated on artificial substrates. Growth characteristics and harvest timing for artificial cultivation have been established by Japanese researchers.
• Research Status: Subject of active pharmacological research at multiple Japanese institutions, with studies published on neuroprotective, antioxidant, and metabolic effects.

Korea

• Status: Known as Champanul. Cultivated and consumed as a culinary mushroom.
• Research Status: Korean institutions have contributed significant research on anti-asthmatic, anti-obesity, and antidiabetic properties.

United States

• FDA Status: No GRAS determination. Not commonly available in the US market.
• Research Interest: Known in natural products literature for its unique phenylpentane-derived neuroprotective compounds.

European Union

• Status: Not authorized under Novel Food Regulation. Not commonly available in European markets.

Conditions & Indications

Primary Indications (Animal Model Evidence)

• Neuroprotection and neurodegenerative disease — Phenylpentane derivatives from M. aitchisonii mycelium enhance dopamine release by up to 4-fold in rat brain striatal slices (1-phenyl-3-pentanol at 2.5 micrograms induced a 4-fold dopamine increase; a half-dose produced a 2.5-fold increase). Dietary intake significantly increased NGF (nerve growth factor) concentrations in the cerebral cortex and hippocampus of newborn rats at days 7 and 14. In a transient global ischemia model, M. aitchisonii feeding normalized dopamine turnover rates in the cerebral cortex to sham-operated levels, demonstrating protection against ischemia-induced monoamine metabolism disruption.
• Oxidative stress and Nrf2-mediated cytoprotection — Extract of M. aitchisonii induces NQO1 (NAD(P)H:quinone oxidoreductase 1) enzymatic activity and ARE (antioxidant response element) reporter activity through activation of the Nrf2 transcription factor. Among 11 active compounds isolated (including three novel ones), dihydro-4-phenyl-2(3H)-furanone was the most potent NQO1 inducer. Nrf2 activation drives expression of a battery of antioxidative and phase II detoxifying enzymes that protect cells against oxidative and electrophilic stress.
• Asthma and allergic airway inflammation — M. aitchisonii dose-dependently suppressed white blood cell counts, eosinophils, and IgE levels in ovalbumin-induced asthma mice. Treatment recovered asthmatic morphological changes including mucous hyper-secretion, epithelial hyperplasia, and eosinophil infiltration. Regulatory mechanism involved modulation of Th1/Th2 transcription factors (T-bet and GATA-3) and associated cytokine profiles. Candidate active compounds identified as nicotinic acid, oleic acid, and linoleic acid.

Secondary Indications (Animal Model Evidence)

• Obesity and metabolic syndrome — Dietary supplementation with powdered M. aitchisonii (MAP) at 1%, 3%, and 5% concentrations in high-fat diet mice significantly decreased body weight gain, food intake, food efficiency ratio, hepatic cholesterol levels, and adipose tissue weight in a dose-dependent manner. Treatment reduced fatty liver deposits, steatosis, and adipocyte size.
• Diabetes (alpha-glucosidase inhibition) — Mycelial and fruit body extracts demonstrate antidiabetic activities through carbohydrate-digesting enzyme inhibition.
• Antihypertensive effects — An aqueous extract from the fruit body contains antihypertensive substances, though the specific compounds and mechanisms require further characterization.
• Endoplasmic reticulum stress protection — Two novel compounds and six known compounds isolated from M. aitchisonii showed protective activity against ER stress-dependent cell death, relevant to neurodegenerative and metabolic diseases.

Emerging/Preclinical Indications

• Fibrinolysis and thrombolysis — A novel protease fraction (MA-1), characterized as an acid-tolerant chymotrypsin-like metalloprotein, exhibits fibrinolytic activity stronger than plasmin, hydrolyzing all three chains of fibrinogen (Aalpha, Bbeta, and gamma) within 2 hours. This suggests potential application in thrombolytic therapy.
• Cerebral ischemia recovery — M. aitchisonii feeding accelerated normalization of dopamine metabolites (DOPAC and HVA) in the cerebral cortex following transient bilateral carotid artery occlusion, suggesting neuroprotective potential in stroke recovery.
• Acetylcholinesterase inhibition — Comparative studies with Lentinus edodes and Sparassis crispa demonstrated AChE inhibitory activity, potentially relevant to Alzheimer’s disease research.

Mechanism of Action

Primary Mechanisms

1. Phenylpentane-mediated dopamine enhancement Cultured mycelium of M. aitchisonii contains unique phenylpentane derivatives, including 1-phenyl-3-pentanol, that directly enhance dopamine release from brain tissue. Administration of 2.5 micrograms of 1-phenyl-3-pentanol to rat brain striatum slices induced a 4-fold increase in dopamine release, while a half-dose produced a 2.5-fold increase, demonstrating a clear dose-response relationship. This mechanism is distinct from most neurotrophic mushroom compounds (which typically act through growth factor stimulation) in that phenylpentanes appear to directly modulate catecholaminergic neurotransmitter release. The dopaminergic enhancement may explain the traditional culinary appeal of the mushroom and positions it uniquely among medicinal fungi for conditions involving dopamine deficiency.

2. Nerve growth factor (NGF) stimulation Dietary intake of M. aitchisonii significantly increases NGF concentrations in the cerebral cortex and hippocampus. In newborn rats, two M. aitchisonii-fed groups showed significant NGF increases in brain halves at days 7 and 14 compared to control feed. This dual mechanism — direct dopamine enhancement plus NGF stimulation — provides a complementary neuroprotective profile: dopamine modulation addresses acute neurotransmitter function, while NGF stimulation supports long-term neuronal survival, growth, and differentiation in the developing and adult brain.

3. Nrf2-mediated antioxidant enzyme induction M. aitchisonii extract activates the Nrf2 (nuclear factor erythroid 2-related factor 2) transcription factor, which translocates to the nucleus and binds antioxidant response elements (ARE) in the promoters of cytoprotective genes. This induces a coordinated battery of antioxidative enzymes (NQO1, glutathione S-transferases, heme oxygenase-1) and phase II detoxification enzymes. The most potent NQO1-inducing compound was identified as dihydro-4-phenyl-2(3H)-furanone. This activation was confirmed as Nrf2-dependent because the induction was attenuated in peritoneal macrophages from Nrf2-knockout mice.

Secondary Mechanisms

• Th1/Th2 immune regulation (anti-asthmatic): M. aitchisonii modulates the balance between Th1 and Th2 immune responses by affecting the transcription factors T-bet (Th1) and GATA-3 (Th2), Th1-related cytokines, Th2-related cytokines, and proinflammatory cytokines. This rebalancing suppresses the Th2-skewed immune response characteristic of allergic asthma, reducing eosinophil infiltration, IgE production, and mucous hyper-secretion.
• Lipid metabolism modulation (anti-obesity): Powdered M. aitchisonii reduces hepatic cholesterol and adipose tissue through dose-dependent suppression of lipogenesis and reduction of adipocyte hypertrophy. The specific molecular targets in lipid metabolism pathways remain to be characterized.
• ER stress protection: Isolated compounds protect against endoplasmic reticulum stress-dependent cell death, possibly through upregulation of ER chaperones or modulation of the unfolded protein response (UPR) signaling pathway.
• Fibrinolytic protease activity: The MA-1 protease fraction directly degrades fibrinogen and fibrin clots through chymotrypsin-like proteolytic activity, independent of the plasminogen activation system.
• Cerebral ischemia protection: Normalization of dopamine turnover rates (DOPAC/dopamine and HVA/dopamine ratios) following transient global ischemia suggests preservation of dopaminergic neuronal function during and after ischemic insult.

Clinical Evidence Summary

No human clinical trials have been published for Mycoleptodonoides aitchisonii. All pharmacological evidence derives from in vitro studies and animal models. The species has been the subject of a comprehensive published review confirming its versatile applications as a culinary-medicinal mushroom.

Key Research Studies

Evidence Limitations

• No human clinical trials for any indication.
• Neuroprotective studies are conducted in rodent models; translation to human neurodegenerative disease requires clinical validation.
• The phenylpentane-mediated dopamine enhancement has been demonstrated ex vivo and in vivo in rats, but human pharmacokinetics and blood-brain barrier penetration of these compounds are unknown.
• NGF stimulation was demonstrated in newborn rats, and the relevance to adult human neurobiology needs to be established.
• The species is rare and cultivation infrastructure is limited compared to major cultivated medicinal mushrooms.
• Most studies originate from Japanese and Korean research groups; independent replication from diverse research institutions is limited.
• Dosing in animal studies (e.g., 1-5% of diet) does not directly translate to practical human supplementation dosing.
• The fibrinolytic protease (MA-1) was characterized in vitro; in vivo thrombolytic efficacy and safety require assessment.

Safety Profile

General Assessment

Mycoleptodonoides aitchisonii has a long history of consumption as a culinary mushroom in Japan and Korea, establishing a basic safety profile at dietary intake levels. It is recognized as an edible mushroom with no reports of toxicity from dietary consumption. However, formal toxicological assessment (acute toxicity, subchronic toxicity, mutagenicity) has not been published, and the safety of concentrated extracts or supplements at therapeutic doses remains uncharacterized.

Contraindications

• Pregnancy and lactation: Insufficient safety data for concentrated supplements or therapeutic use during pregnancy and lactation. Dietary consumption as a culinary mushroom at normal food intake levels is likely safe based on traditional culinary use, but supplemental doses are not recommended.
• Known mushroom or fungal allergy: Cross-reactivity with other basidiomycete fungi is possible. Discontinue if allergic symptoms occur.
• Dopaminergic medication interactions (theoretical): The dopamine-enhancing phenylpentane compounds could theoretically interact with dopaminergic medications used in Parkinson’s disease, depression, or psychosis.

Drug Interactions

No clinical drug interactions have been documented. Theoretical interactions include:

• Dopaminergic drugs (levodopa, dopamine agonists, MAO-B inhibitors): Phenylpentane derivatives enhance dopamine release; additive dopaminergic effects are theoretically possible. Severity: Theoretical but clinically relevant if validated.
• Antihypertensive agents: Aqueous extracts contain antihypertensive substances; additive blood pressure lowering is possible. Severity: Theoretical.
• Anticoagulants/antiplatelets: The fibrinolytic protease MA-1 is an oral enzyme with unknown in vivo bioavailability, but theoretical additive effects on hemostasis exist. Severity: Theoretical.
• Antidiabetic agents: Alpha-glucosidase inhibitory activity may produce additive hypoglycemic effects. Severity: Theoretical.

Side Effects

No adverse effects have been reported from dietary consumption. Based on the pharmacological profile, potential concerns at high supplemental doses include:

• Gastrointestinal effects from concentrated extracts
• Theoretical dopaminergic side effects (agitation, insomnia) at very high doses of phenylpentane-enriched preparations
• Blood pressure reduction in susceptible individuals

Clinical Dosage

Culinary Consumption

• Dietary intake: Consumed as a culinary mushroom in Japan and Korea during summer and autumn seasons. Typical dietary amounts provide a baseline of bioactive compounds.
• Preparation: Cooked as a food item; traditionally used in Japanese and Korean cuisine. The fruiting body has a pleasant flavor and tender texture.

Supplemental Dosing (Not Clinically Established)

• Anti-obesity study dose: 1-5% of diet as powdered M. aitchisonii (MAP) in mice; human-equivalent doses not established.
• Anti-asthmatic study: Various doses in ovalbumin-induced asthma mice; dose-dependent effects observed but human dosing not extrapolated.
• No standardized human supplementation doses exist. Any therapeutic application should be considered experimental.

Mycelium Extract (Research Context)

• Phenylpentane-enriched mycelial extracts have been used in preclinical neuroprotective studies at various concentrations. Translation to human oral supplementation dosing requires pharmacokinetic studies.

Sources

• Obara Y, Nakahata N, Kita T, et al. Enhancing effect of Mycoleptodonoides aitchisonii on synthesis of nerve growth factor and releasing dopamine in the rat brain. Biol Pharm Bull. 2004;27(3):390-393
• Obara Y, Hoshino T, Marcotullio MC, et al. Conductor compounds of phenylpentane in Mycoleptodonoides aitchisonii mycelium enhance the release of dopamine from rat brain striatum slices. Biol Pharm Bull. 2004;27(7):1119-1122
• Obara Y, Nakahata N, Kita T, et al. Mycoleptodonoides aitchisonii affects brain nerve growth factor concentration in newborn rats. Biol Pharm Bull. 2005;28(1):141-144
• Lee IS, Nishikawa A, Sawamura K, Kang KS. Extract of the mushroom Mycoleptodonoides aitchisonii induces a series of anti-oxidative and phase II detoxifying enzymes through activation of the transcription factor Nrf2. Food Chem. 2012;131(4):1147-1154
• Sato M, Obara Y, Nakahata N. Effect of the edible mushroom Mycoleptodonoides aitchisonii on transient global ischemia-induced monoamine metabolism changes in rat cerebral cortex. Biol Pharm Bull. 2011;34(11):1730-1735
• Yoon CS, Kim DC, Ko WM, et al. Endoplasmic reticulum stress suppressive compounds from the edible mushroom Mycoleptodonoides aitchisonii. J Nat Prod. 2014;77(7):1671-1675
• Lee JS, Kim DH, Lee CM, et al. Ameliorating effect of Mycoleptodonoides aitchisonii on high-fat diet-induced obese mice. J Korean Soc Food Sci Nutr. 2014;43(8):1166-1173
• Kim J, Kim H, Lee S, et al. Mycoleptodonoides aitchisonii suppresses asthma via Th2 and Th1 cell regulation in an ovalbumin-induced asthma mouse model. Mol Med Rep. 2018;17(1):11-20
• Choi JH, Park YH, Lee IS, et al. Partial purification and biochemical evaluation of protease fraction (MA-1) from Mycoleptodonoides aitchisonii and its fibrinolytic effect. Antioxidants. 2023;12(8):1558
• Bae JS, Lee IS, Kim DH. Versatile applications of the culinary-medicinal mushroom Mycoleptodonoides aitchisonii (Berk.) Maas G. (Higher Basidiomycetes): a review. Int J Med Mushrooms. 2013;15(2):123-131
• Obara Y, Hoshino T, Marcotullio MC, et al. Derivatives of phenylpentanone in cultured mycelium of Mycoleptodonoides aitchisonii and the syntheses of their compounds. Yakugaku Zasshi. 2008;128(12):1831-1836
• Lee IS, Kim DH, Youn SH, et al. Antioxidant and antidiabetic activities of mycelial and fruit-body extracts from Mycoleptodonoides aitchisonii. Biotechnol Bioprocess Eng. 2016;21:758-766
• Moon HI, Kim MR, Cho SJ, et al. Comparison of constituents, antioxidant potency, and acetylcholinesterase inhibition in Lentinus edodes, Sparassis crispa, and Mycoleptodonoides aitchisonii. Food Sci Biotechnol. 2013;22(6):1747-1751

Connections

• Compare with Lion’s Mane (Hericium erinaceus) — the most well-known neurotrophic medicinal mushroom; both stimulate NGF production, but M. aitchisonii additionally enhances dopamine release through unique phenylpentane compounds, providing a complementary neuroprotective mechanism; Lion’s Mane acts primarily through hericenones and erinacines stimulating NGF/BDNF synthesis, while M. aitchisonii acts through direct catecholaminergic modulation
• Compare with Hericium coralloides and Hericium americanum — related tooth fungi with NGF-stimulating properties; M. aitchisonii belongs to a different family (Meruliaceae vs. Hericiaceae) but converges on neurotrophic activity through different compound classes
• Compare with Sparassis crispa (Cauliflower Mushroom) — Japanese culinary-medicinal mushroom with overlapping antioxidant and AChE-inhibitory activities; direct comparative studies have been published
• The Nrf2-mediated antioxidant enzyme induction mechanism connects M. aitchisonii to the broader Nrf2-activating pharmacology found across plant and fungal bioactives, including sulforaphane from broccoli and curcumin from turmeric
• The anti-asthmatic Th1/Th2 rebalancing mechanism parallels the anti-allergic properties of Reishi ganoderic acids, which also modulate allergic immune responses through inhibition of histamine release and immune cell regulation
• The fibrinolytic protease MA-1 represents a class of mushroom-derived thrombolytic enzymes paralleling nattokinase from Bacillus subtilis fermentation, suggesting a functional convergence between fungal and bacterial fibrinolytic enzyme production